Navigation Links
New Webinar Hosted by Xtalks Prepares Manufacturers for AMNOG Regulations and the Future of Access and Pricing
Date:8/25/2014

Toronto, Canada (PRWEB) August 25, 2014

Introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in 2011 and the resulting requirements for benefit assessment have fundamentally changed the conditions of market access and pharmaceutical pricing in Germany. The aim of this mandatory evaluation of clinical evidence was to limit the cost of pharmaceuticals and tackle the price monopoly of drug manufacturers in Germany.

While this has successfully been achieved, it has also brought with it further implications beyond the immediate German market, particularly for those countries that use Germany as a price reference. The open nature in which the clinical evidence and especially the critical aspects in these assessments is shared publically has potential impact on a product’s value story with payers in many other jurisdictions. For organizations working in this market or utilizing German price points for market access strategy, understanding these interconnections is critical.

Key take aways of this program include:

  •     Understanding of current AMNOG process
  •     Implications of AMNOG evaluation
  •     Impact of publically available assessment on value story
  •     Overview of price discount trends, both average and unique examples
  •     Future growth beyond current AMNOG framework

For more information or to register for this webinar, visit: AMNOG – German Regulation in the Past, Present and Future.

About Xcenda and Herescon
Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. In December of 2013, Herescon GmbH, one of the largest research and consulting boutiques in Germany focused on market access and health economics services, joined this experienced team. As part of AmerisourceBergen Corporation, a leading global healthcare solutions company, the combined bench of Xcenda and Herescon consultants supports pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, these collaborative partners help manufacturers identify, demonstrate, and deliver their brand’s value proposition to key healthcare stakeholders. For more information visit on Xcenda, visit http://www.xcenda.com/. For more information on Herescon, visit http://www.herescon.com/.

About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/sponsorship.ashx.

Contact:
Michelle Tran
Tel: +1 (416) 977-6555 ext 352
Email: mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12116389.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks
2. Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks
3. Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks
4. China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks
5. The Voice of the Patient in Clinical Trials: Hearing It, Understanding It, New Webinar Hosted by Xtalks
6. Protocol Pooling and Point of Distribution (PoD) Clinical Labeling, Live Webinar Hosted by Xtalks
7. Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks
8. The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks
9. Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks
10. Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks
11. Implementing Risk-based Monitoring, Using Oncology Examples, New Webinar July 31st Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... SAN FRANCISCO , Sept. 19, 2017 ... Management Solutions (VLMS) is pleased to announce the strategic ... VTI to provide clients with validation services using the ... a partner, VTI will provide clients with efficient and ... be a marketing partner for the ValGenesis VLMS system. ...
(Date:9/19/2017)... ... September 19, 2017 , ... Band-LOK, ... applications, announced today that two new patents have been allowed by the USPTO ... of Band-LOK, said, “We continue to explore additional clinically-relevant designs for both the ...
(Date:9/18/2017)... CALIFORNIA (PRWEB) , ... September 18, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... the ServiceMax Maximize 2017 conference. , What: Digital Transformation in Medical Device – ...
(Date:9/14/2017)... PA and London UK (PRWEB) , ... September ... ... will gather the most innovative minds in pharma and biotech at the third ... a two-day collaborative conference that brings together the world’s most progressive clinical research ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):